CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists, hematology-oncology fellows, pathologists, nurse practitioners, clinical nurse specialists, pharmacists and other healthcare providers involved in the treatment of multiple myeloma.
  
  LEARNING OBJECTIVES

  • Customize the use of induction, consolidation and maintenance therapeutic approaches for multiple myeloma (MM) in the transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
  • Appreciate available clinical trial data informing the use of monoclonal antibody therapy directed at CD38 as a component of treatment for patients with MM, and effectively identify when and how this strategy should be integrated into clinical management.
  • Recognize clinical investigator perspectives with regard to minimal residual disease (MRD) status as a predictor of long-term outcomes with therapy, and use this information to determine the potential role of MRD assays in the protocol and nonresearch management of MM.
  • Consider published research findings and other clinical factors in the best-practice selection, sequencing or combining of established regimens in the care of patients with relapsed/refractory MM.
  • Develop an understanding of the mechanisms of action of and pivotal clinical trial findings with recently FDA-approved novel therapies (eg, isatuximab, selinexor, belantamab mafodotin, melflufen) to facilitate the integration of these agents into MM management algorithms.
  • Appreciate available data documenting the activity of chimeric antigen receptor T-cell therapy targeting BCMA in MM, and use this knowledge to identify patients who may be appropriate for this approach within or outside of a protocol setting.
  • Recall the design of ongoing clinical trials evaluating novel agents and therapeutic strategies for MM, and counsel appropriate patients about availability and participation.

  CE ACCREDITATION AND CREDIT DESIGNATION STATEMENTS
  In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
  
  PHYSICIANS: CME credit is no longer available for this issue
  
  NURSES: NCPD credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  Video Program: This activity consists of a video component.
  CME/NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.
  
  All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.
  
  This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
  
  All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.
  
  FACULTY — The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:  
  
  Muhamed Baljevic, MD
  Assistant Professor of Medicine
  Division of Hematology/Oncology, Department of Internal Medicine
  Fred and Pamela Buffett Cancer Center
  University of Nebraska Medical Center
  Omaha, Nebraska
  
  Advisory Boards: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation; Research Support: Amgen Inc, Exelixis Inc.
  
  Joseph Mikhael, MD
  Professor, Applied Cancer Research and Drug Discovery
  Translational Genomics Research Institute
  City of Hope Cancer Center
  Phoenix, Arizona
  
  Consulting Agreements: Amgen Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc.
  
  Nina Shah, MD
  Professor of Clinical Medicine
  Division of Hematology Oncology
  University of California, San Francisco
  San Francisco, California
  
  Consulting Agreements: Amgen Inc, CareDx, CSL Behring, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Kite, A Gilead Company, Oncopeptides, Sanofi Genzyme; Contracted Research: bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Nektar, Poseida Therapeutics, Precision BioSciences, Sutro Biopharma, TeneoBio.
  
  Moderator
  Robert Z Orlowski, MD, PhD
  Florence Maude Thomas Cancer Research Professor
  Department of Lymphoma and Myeloma
  Professor, Department of Experimental Therapeutics
  Director, Myeloma Section
  Division of Cancer Medicine
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Amgen Inc, BioTheryX Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Neoleukin Therapeutics, Oncopeptides, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Clinical Research: CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals USA Inc; Laboratory Research: BioTheryX Inc, Heidelberg Pharma, Pfizer Inc; Ownership Interest: Asylia Therapeutics Inc (founder with equity interest and director, scientific advisory board).
  
  UNMC AND RESEARCH TO PRACTICE CE PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS —The below planning committee members have nothing to disclose:
  Neil Love, MD — RTP President and Planner, Atif Hussein, MD — RTP Reviewer, Renee Paulin, MSN, RN, CWOCN — UNMC Planner and Reviewer, Brenda Ram, CMP, CHCP — UNMC Planner, Michele Williams, DNP, AGPCNP-BC— RTP Reviewer, and Kathryn Ault Ziel, PhD—RTP Staff and Planner.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and UNMC do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Bristol-Myers Squibb Company, Oncopeptides and Takeda Oncology.
  
  Release date: October 20, 2021
  Expiration date: October 20, 2022